title: Advances in the management of skin cancer.
abstract: Skin cancer is one of the most commonly diagnosed cancers in the world today in both humans and our pet population. Advances in molecular techniques are now affording us an opportunity to develop therapeutics targeted at specific cancer-related cellular pathways. However, despite progress in conventional treatments, such as chemotherapy and radiation, and the new targeted therapies, some cancers, such as melanoma and cutaneous lymphoma, continue to cause significant mortality and morbidity. This short synopsis is not complete but is aimed at providing an insight into current advanced treatments and horizon therapies for cutaneous malignancies in dogs and cats with comparative aspects.
authors: Royal (Dick) School of Veterinary Studies and Roslin Institute, Easter Bush, Midlothian EH25 9RG, UK.
authors: Pamela D
authors: PD
authors: Martin
authors: David J
authors: DJ
authors: Argyle
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology; D002371:Cat Diseases / Q000628:therapy*; D002415:Cats; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D006655:Histone Deacetylases; D006801:Humans; D008545:Melanoma / Q000517:prevention & control / Q000662:veterinary; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012176:Retinoids / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000517:prevention & control / Q000628:therapy / Q000662:veterinary*; D051193:Toll-Like Receptors / Q000819:agonists; D019444:Vaccines, DNA / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D012176:Retinoids; D051193:Toll-Like Receptors; D019444:Vaccines, DNA; D048493:Proto-Oncogene Proteins B-raf; D006655:Histone Deacetylases